Reply to Tuomas Mirtti and Tero Aittokallio's Letter to the Editor re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40. Clinical Utility of Trial-estimated Prognostic Models.
Seyednasrollah, Fatemeh
Reply to Tuomas Mirtti and Tero Aittokallio's Letter to the Editor re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40. Clinical Utility of Trial-estimated Prognostic Models. [electronic resource] - European urology 09 2017 - e70-e71 p. digital
Publication Type: Letter; Research Support, Non-U.S. Gov't; Comment
1873-7560
10.1016/j.eururo.2017.04.031 doi
Humans
Male
Prognosis
Prostatic Neoplasms, Castration-Resistant
Reply to Tuomas Mirtti and Tero Aittokallio's Letter to the Editor re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40. Clinical Utility of Trial-estimated Prognostic Models. [electronic resource] - European urology 09 2017 - e70-e71 p. digital
Publication Type: Letter; Research Support, Non-U.S. Gov't; Comment
1873-7560
10.1016/j.eururo.2017.04.031 doi
Humans
Male
Prognosis
Prostatic Neoplasms, Castration-Resistant